The latest news for pharma industry insiders.
Enhancing Empowerment in Patient-Focused Research
How the inclusion of measures centered on net treatment benefit can drive an effective multifaceted approach.
NIH Tests New PrEP Delivery Method
Researchers are currently enrolling participants to test the effectiveness of a rectal douche containing the antiretroviral drug tenofovir in a study that is expected to finish in January 2026.
Trump Wants RFK Jr. to ‘Go Wild’ on Healthcare. Investors Need Not Panic.
The vaccine skeptic may find it hard to enact sweeping changes to American healthcare.
National Ataxia Foundation Hosts Congressional Briefing with Bill Nye, The Science Guy
The National Ataxia Foundation (NAF) partnered with members of Congress to host an informational meeting for legislators, their staff and other interested parties to provide education regarding Spinocerebellar Ataxia (SCA), a group of rare and debilitating hereditary neurodegenerative diseases that frequently impact multiple family members at the same time, with no cure or FDA-approved treatment.
Anthony W. Luttenberger on LinkedIn
Learn from UBC on how artificial intelligence (AI) is benefitting patients, prescribers and biopharmaceutical companies to increase adherence and compliance driving up outcomes, improving efficiency & overall cost of care.
It is well documented that the vast majority of expense to bring treatments & therapies to market is spent on drug development and new product launches, yet the key to brand success is getting patients on therapy and staying on therapy over time.
Listen to Amanda Scholz, UBC's Senior Clinical Program Manager, as she speaks with Pharmaceutical Commerce Magazine to discusses the important role that clinical adherence and patient support programs play in empowering patients and bolstering medication persistence.
To learn more, reach out to schedule a call.
#patientaccess #patientadherence #UBC Eric Reichwein, MBA Constance Taylor, MBA
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs